Enzymatica und Sanofi Consumer Health Care, Teil des französischen Pharmakonzerns Sanofi, haben eine Vereinbarung über Marketing, Vertrieb und Verkauf von Enzymaticas Kältespray ColdZyme in Frankreich und Italien geschlossen. Die beiden Länder repräsentieren mit einer Gesamtbevölkerung von fast 130 Millionen Einwohnern einige der größten OTC-Märkte in Europa. Sanofi geht davon aus, ColdZyme unter ihren etablierten Markennamen auf diesen Märkten während der Husten- und Erkältungssaison 2020/2021 einzuführen.
Sanofi ist mengenmäßig die Nummer eins und wertmäßig die Nummer zwei auf dem europäischen Markt für Verbrauchergesundheitspflege nach GSK/Pfizer mit einem europäischen Marktanteil von etwa 5,8%. Weltweit gehört Sanofi zu den Top 4 Global Players auf dem OTC-Markt, der Markt wird auf 126 Milliarden Euro geschätzt.
PR Newswire
21.10.2020 | 11:16
20 Leser
Artikel bewerten:
(0)
Enzymatica enters agreement with Sanofi for covering France and Italy on common cold spray Coldzyme
STOCKHOLM, Oct. 21, 2020 /PRNewswire/ -- Enzymatica and Sanofi Consumer Health Care, part of the French pharmaceutical group Sanofi, have entered an agreement for marketing, distribution and sales of Enzymatica's cold spray ColdZyme in France and Italy. The two countries represent some of the largest OTC markets in Europe with a total population of nearly 130 million. Sanofi expects to launch ColdZyme under their established trademarks in these markets during the cough & cold seasons 2020/2021.
Sanofi is ranked number one in volume and number two in value on the European consumer health care market after GSK/Pfizer with a European market share of about 5,8%. Globally, Sanofi is part of the top 4 global players in the OTC market, market is estimated to euro 126 billion.
"We are very excited to enter into an agreement of this magnitude with Sanofi, one of the leading and largest pharmaceutical group in the world within consumer health care. It gives ColdZyme an opportunity for further market penetration in Europe," says Claus Egstrand, Chief Operating Officer at Enzymatica.
"We are very pleased to have entered into a collaboration with Enzymatica. Its medical device ColdZyme mouth spray against common cold, has recently received the highest classification, class III, according to the Medical Device Directive within the EU. The enzyme barrier technology of the product hinders virus to spread and multiply and is supported by strong documentation. "We see, with Coldzyme, a real opportunity to better respond to the consumer needs for effective solutions against common cold virus and related immune defense, says Isabelle Van Rycke, Head of Sanofi Consumer Health Care Europe."
Sanofi has strong market positions in the French and Italian cough & cold market. In France, the cough & cold market has an estimated value of euro 0.8 billion. Sanofi has the leading market position within this segment with a market share of about 15%. In Italy the cough & cold market has an estimated value of about euro 1.1 billion, where Sanofi is the 4th largest player.
The cough & cold market in these two markets amounts toeuro 1,9 billion which can be compared to the Swedish cough & cold market at pharmacies of about euro 85 million. ColdZyme currently has a market share of about 7% in Sweden after being on the market for seven years,
Source for market data above for Global market: Nicolas Hall FY 2019 / for France, and Italy: / IQVIA MAT 7/2019.
Source for market data above for Sweden: IQVIA w.37
https://www.finanznachrichten.de/nachric...me-008.htm
Sanofi ist mengenmäßig die Nummer eins und wertmäßig die Nummer zwei auf dem europäischen Markt für Verbrauchergesundheitspflege nach GSK/Pfizer mit einem europäischen Marktanteil von etwa 5,8%. Weltweit gehört Sanofi zu den Top 4 Global Players auf dem OTC-Markt, der Markt wird auf 126 Milliarden Euro geschätzt.
PR Newswire
21.10.2020 | 11:16
20 Leser
Artikel bewerten:
(0)
Enzymatica enters agreement with Sanofi for covering France and Italy on common cold spray Coldzyme
STOCKHOLM, Oct. 21, 2020 /PRNewswire/ -- Enzymatica and Sanofi Consumer Health Care, part of the French pharmaceutical group Sanofi, have entered an agreement for marketing, distribution and sales of Enzymatica's cold spray ColdZyme in France and Italy. The two countries represent some of the largest OTC markets in Europe with a total population of nearly 130 million. Sanofi expects to launch ColdZyme under their established trademarks in these markets during the cough & cold seasons 2020/2021.
Sanofi is ranked number one in volume and number two in value on the European consumer health care market after GSK/Pfizer with a European market share of about 5,8%. Globally, Sanofi is part of the top 4 global players in the OTC market, market is estimated to euro 126 billion.
"We are very excited to enter into an agreement of this magnitude with Sanofi, one of the leading and largest pharmaceutical group in the world within consumer health care. It gives ColdZyme an opportunity for further market penetration in Europe," says Claus Egstrand, Chief Operating Officer at Enzymatica.
"We are very pleased to have entered into a collaboration with Enzymatica. Its medical device ColdZyme mouth spray against common cold, has recently received the highest classification, class III, according to the Medical Device Directive within the EU. The enzyme barrier technology of the product hinders virus to spread and multiply and is supported by strong documentation. "We see, with Coldzyme, a real opportunity to better respond to the consumer needs for effective solutions against common cold virus and related immune defense, says Isabelle Van Rycke, Head of Sanofi Consumer Health Care Europe."
Sanofi has strong market positions in the French and Italian cough & cold market. In France, the cough & cold market has an estimated value of euro 0.8 billion. Sanofi has the leading market position within this segment with a market share of about 15%. In Italy the cough & cold market has an estimated value of about euro 1.1 billion, where Sanofi is the 4th largest player.
The cough & cold market in these two markets amounts toeuro 1,9 billion which can be compared to the Swedish cough & cold market at pharmacies of about euro 85 million. ColdZyme currently has a market share of about 7% in Sweden after being on the market for seven years,
Source for market data above for Global market: Nicolas Hall FY 2019 / for France, and Italy: / IQVIA MAT 7/2019.
Source for market data above for Sweden: IQVIA w.37
https://www.finanznachrichten.de/nachric...me-008.htm
